Immunomedics, Inc. (IMMU) Position Increased by NEXT Financial Group Inc

NEXT Financial Group Inc boosted its stake in Immunomedics, Inc. (NASDAQ:IMMU) by 6.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,750 shares of the biopharmaceutical company’s stock after buying an additional 7,100 shares during the quarter. NEXT Financial Group Inc owned approximately 0.07% of Immunomedics worth $1,298,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in IMMU. UBS Asset Management Americas Inc. boosted its stake in Immunomedics by 361.2% in the 1st quarter. UBS Asset Management Americas Inc. now owns 67,301 shares of the biopharmaceutical company’s stock valued at $435,000 after buying an additional 52,709 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in Immunomedics by 49.6% in the first quarter. Parametric Portfolio Associates LLC now owns 167,077 shares of the biopharmaceutical company’s stock worth $1,081,000 after purchasing an additional 55,392 shares in the last quarter. FMR LLC boosted its stake in Immunomedics by 34.6% in the first quarter. FMR LLC now owns 1,524,463 shares of the biopharmaceutical company’s stock worth $9,863,000 after purchasing an additional 391,815 shares in the last quarter. Teachers Advisors LLC boosted its stake in Immunomedics by 2.1% in the first quarter. Teachers Advisors LLC now owns 189,537 shares of the biopharmaceutical company’s stock worth $1,226,000 after purchasing an additional 3,876 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Immunomedics by 11.9% in the first quarter. Vanguard Group Inc. now owns 4,416,533 shares of the biopharmaceutical company’s stock worth $28,574,000 after purchasing an additional 468,314 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Immunomedics, Inc. (IMMU) Position Increased by NEXT Financial Group Inc” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.com-unik.info/2017/11/20/immunomedics-inc-immu-position-increased-by-next-financial-group-inc.html.

A number of research firms have commented on IMMU. Zacks Investment Research raised Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Wednesday, October 4th. Jefferies Group LLC boosted their price objective on Immunomedics from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, October 9th. BidaskClub raised Immunomedics from a “hold” rating to a “buy” rating in a research note on Wednesday, August 23rd. Finally, Cowen and Company reissued an “outperform” rating and issued a $15.00 price objective on shares of Immunomedics in a research note on Monday, July 24th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $15.33.

In other news, Director Cynthia L. Goldenberg sold 40,000 shares of the business’s stock in a transaction on Monday, August 28th. The stock was sold at an average price of $10.72, for a total transaction of $428,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David M. Goldenberg sold 20,000 shares of the business’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $12.64, for a total value of $252,800.00. The disclosure for this sale can be found here. In the last three months, insiders sold 100,000 shares of company stock worth $1,051,200. Insiders own 6.60% of the company’s stock.

Immunomedics, Inc. (NASDAQ IMMU) traded down $0.25 during trading on Monday, reaching $11.75. The company’s stock had a trading volume of 2,294,800 shares, compared to its average volume of 3,099,057. The company has a current ratio of 0.74, a quick ratio of 0.74 and a debt-to-equity ratio of -0.29. Immunomedics, Inc. has a one year low of $2.92 and a one year high of $14.48.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

What are top analysts saying about Immunomedics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Immunomedics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit